HF Advisory Group LLC Has $6.64 Million Stock Position in Becton, Dickinson and Company $BDX

HF Advisory Group LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 559.3% during the fourth quarter, HoldingsChannel reports. The firm owned 34,230 shares of the medical instruments supplier’s stock after acquiring an additional 29,038 shares during the quarter. HF Advisory Group LLC’s holdings in Becton, Dickinson and Company were worth $6,643,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Legacy Capital Wealth Partners LLC lifted its stake in Becton, Dickinson and Company by 18.3% in the fourth quarter. Legacy Capital Wealth Partners LLC now owns 2,542 shares of the medical instruments supplier’s stock valued at $493,000 after acquiring an additional 394 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Becton, Dickinson and Company by 3.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 65,768 shares of the medical instruments supplier’s stock valued at $12,764,000 after purchasing an additional 2,378 shares during the period. Jamison Private Wealth Management Inc. lifted its stake in Becton, Dickinson and Company by 15.3% in the 4th quarter. Jamison Private Wealth Management Inc. now owns 2,979 shares of the medical instruments supplier’s stock valued at $578,000 after purchasing an additional 396 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Becton, Dickinson and Company by 1.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 13,411 shares of the medical instruments supplier’s stock worth $2,614,000 after purchasing an additional 136 shares during the period. Finally, Financial Planning Hawaii Inc. bought a new position in Becton, Dickinson and Company during the fourth quarter worth about $345,000. 86.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

BDX has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Citigroup cut their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Finally, Argus decreased their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Six equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $191.62.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 2,713 shares of company stock valued at $536,881. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Trading Down 0.4%

Shares of NYSE:BDX opened at $156.61 on Thursday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The business has a 50 day moving average of $177.66 and a 200-day moving average of $186.92. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market cap of $44.59 billion, a PE ratio of 25.55, a P/E/G ratio of 11.40 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.